AbbVie Stock Rises on Stronger-Than-Expected Results, Profit Outlook Lift
AbbVie shares rose Friday after the drugmaker's first-quarter results came in above analysts' expectations.
AbbVie shares rose Friday after the drugmaker's first-quarter results came in above analysts' expectations.
U.S. equities were mixed at midday as the market renewed its focus on the possible impact of new tariffs.
The S&P 500 index fell as much as 12% from April 2, when Trump announced new tariffs against trade partners. It's just about 3% lower now.
Deloitte predicts private market investments among retail investors will grow “exponentially” in the next five years.
Tesla shares jumped Friday, extending their recent rally after CEO Elon Musk said he would spend more of his time focusing on Tesla, as the Trump administration moved to loosen rules around self-driving cars.
Avantor's CEO is stepping down after 11 years as head of the chemical and other life sciences company.
The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.
Shares of Google parent Alphabet climbed Friday as several analysts raised their price targets for the stock after the tech titan delivered better-than-expected quarterly results and touted the early success of AI features.
Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined.
T-Mobile added fewer new phone customers than anticipated in the first quarter, sending shares lower.